---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-001664"
form_type: "8-K"
ticker: null
cik: "0001173281"
company_name: "NeuBase Therapeutics, Inc."
filed_at: "2025-01-07T23:59:59+00:00"
generated_at: "2026-05-28T07:54:04.029046+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# NeuBase approves $0.13/share initial distribution in liquidation; CEO/CFO resigns, board change

## Summary
- Todd Branning resigns as Interim CEO and CFO effective Jan 3, 2025; appointed to Board on Jan 4.
- Dov Goldstein resigns from Board effective immediately on Jan 4, 2025.
- Board approved Plan of Distribution: initial distribution of ~$500,000 ($0.13 per share) to stockholders of record June 26, 2024.
- Company is in process of dissolution; shares delisted from Nasdaq in May 2024.

## SEC filing metadata
- accession: 0001104659-25-001664
- form_type: 8-K
- cik: 0001173281
- company_name: NeuBase Therapeutics, Inc.
- filed_at: 2025-01-07T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1173281/000110465925001664/0001104659-25-001664-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1173281/000110465925001664/tm252159d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-001664
- JSON: https://secwatch.observer/filing/0001104659-25-001664.json
- Plain text: https://secwatch.observer/filing/0001104659-25-001664.txt

## Key facts
- Executive change
  Todd P. Branning was appointed as Director at NeuBase Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: On January 4, 2025, Mr. Branning was appointed to the Board of Directors of the Company (the “Board”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1173281/000110465925001664/0001104659-25-001664-index.htm
- Executive change
  Todd P. Branning resigned as Interim Chief Executive Officer and Chief Financial Officer at NeuBase Therapeutics, Inc..
  - Action: resigned
  - Role: Interim Chief Executive Officer and Chief Financial Officer
  source text: Todd P. Branning, the Interim Chief Executive Officer and Chief Financial Officer of NeuBase Therapeutics, Inc. (the “Company”), notified the Company of his resignation as interim Chief Executive Officer and Chief Financial Officer, effective as of close of business on January 3, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1173281/000110465925001664/0001104659-25-001664-index.htm
- Executive change
  Dov A. Goldstein resigned as Director at NeuBase Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On January 4, 2025, Dov A. Goldstein, M.D. notified the Company of his resignation as a member of the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1173281/000110465925001664/0001104659-25-001664-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.